126 related articles for article (PubMed ID: 9139880)
1. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
[TBL] [Abstract][Full Text] [Related]
2. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
3. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
Shih L; Ong GL; Burton J; Mishina D; Goldenberg DM; Mattes MJ
Cancer Immunol Immunother; 2000 Jul; 49(4-5):208-16. PubMed ID: 10941903
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
5. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
6. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
[TBL] [Abstract][Full Text] [Related]
7. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo.
Stein R; Goldenberg DM; Ong GL; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Sep; 38(9):1392-400. PubMed ID: 9293796
[TBL] [Abstract][Full Text] [Related]
8. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
9. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
10. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
Michel RB; Ochakovskaya R; Mattes MJ
Clin Cancer Res; 2002 Aug; 8(8):2632-9. PubMed ID: 12171895
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
12. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
Lindén O; Tennvall J; Hindorf C; Cavallin-Ståhl E; Lindner KJ; Ohlsson T; Wingårdh K; Strand SE
Acta Oncol; 2002; 41(3):297-303. PubMed ID: 12195750
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
15. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
16. Single-cell cytotoxicity with radiolabeled antibodies.
Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
[TBL] [Abstract][Full Text] [Related]
17. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
18. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
